ICAD INC (ICAD)
US44934S2068 - Common Stock
Overall ICAD gets a fundamental rating of 3 out of 10. We evaluated ICAD against 37 industry peers in the Health Care Technology industry. No worries on liquidiy or solvency for ICAD as it has an excellent financial health rating, but there are worries on the profitability. ICAD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ICAD had negative earnings in the past year.
In the past year ICAD has reported a negative cash flow from operations.
ICAD had negative earnings in each of the past 5 years.
In the past 5 years ICAD always reported negative operating cash flow.
1.2 Ratios
ICAD has a Return On Assets of -5.85%. This is in the better half of the industry: ICAD outperforms 72.22% of its industry peers.
With a decent Return On Equity value of -7.35%, ICAD is doing good in the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.85% | ||
| ROE | -7.35% | ||
| ROIC | N/A |
ROA(3y)-18.74%
ROA(5y)-24.07%
ROE(3y)-25.94%
ROE(5y)-80.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ICAD has a better Gross Margin (86.05%) than 88.89% of its industry peers.
ICAD's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ICAD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.05% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.9%
GM growth 5Y2.4%
2. Health
2.1 Basic Checks
ICAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ICAD has been increased compared to 1 year ago.
ICAD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ICAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -5.61, we must say that ICAD is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.61, ICAD is not doing good in the industry: 80.56% of the companies in the same industry are doing better.
ICAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.61 |
ROIC/WACCN/A
WACC9.08%
2.3 Liquidity
A Current Ratio of 4.24 indicates that ICAD has no problem at all paying its short term obligations.
ICAD has a better Current ratio (4.24) than 83.33% of its industry peers.
ICAD has a Quick Ratio of 4.13. This indicates that ICAD is financially healthy and has no problem in meeting its short term obligations.
ICAD has a Quick ratio of 4.13. This is amongst the best in the industry. ICAD outperforms 80.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.24 | ||
| Quick Ratio | 4.13 |
3. Growth
3.1 Past
ICAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.67%, which is quite impressive.
Looking at the last year, ICAD shows a very negative growth in Revenue. The Revenue has decreased by -38.02% in the last year.
The Revenue has been decreasing by -7.53% on average over the past years.
EPS 1Y (TTM)66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)-38.02%
Revenue growth 3Y-16.46%
Revenue growth 5Y-7.53%
Sales Q2Q%3.61%
3.2 Future
ICAD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.97% yearly.
Based on estimates for the next years, ICAD will show a quite strong growth in Revenue. The Revenue will grow by 13.18% on average per year.
EPS Next Y-25.18%
EPS Next 2Y0.16%
EPS Next 3Y15.97%
EPS Next 5YN/A
Revenue Next Year-4%
Revenue Next 2Y9.23%
Revenue Next 3Y13.18%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ICAD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ICAD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ICAD's earnings are expected to grow with 15.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.16%
EPS Next 3Y15.97%
5. Dividend
5.1 Amount
ICAD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ICAD INC
NASDAQ:ICAD (11/14/2024, 8:27:09 PM)
Premarket: 1.76 -0.02 (-1.4%)1.785
-0.55 (-23.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap47.37M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.85% | ||
| ROE | -7.35% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.05% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.24 | ||
| Quick Ratio | 4.13 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)66.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-25.18%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-38.02%
Revenue growth 3Y-16.46%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y